Source link : https://www.newshealth.biz/health-news/new-car-t-cell-therapy-approved-for-leukemia/
The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults, the agency announced on Friday. Of note, unlike other CAR T-cell therapies, the CD19-directed genetically modified autologous T-cell immunotherapy will have no requirement for a Risk Evaluation and Mitigation Strategy (REMS) program. Approval was supported […]
Author : News Health
Publish date : 2024-11-08 22:46:12
Copyright for syndicated content belongs to the linked Source.